Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Lanepitant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 20/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lanepitant SCHEMBL7823239 | 0.99 | TACR1 (0.99) | TACR1 | |
| Lanepitant SCHEMBL9079078 | 0.99 | TACR1 (0.99) | TACR1 | |
| Lanepitant SCHEMBL30695554 | 0.99 | TACR1 (1.00) | TACR1 | |
| Lanepitant SCHEMBL30522773 | 0.99 | TACR1 (1.00) | TACR1 | |
| Lanepitant SCHEMBL6904907 | 0.99 | TACR1 (1.00) | TACR1 | |
| Lanepitant SCHEMBL14421491 | 0.99 | TACR1 (1.00) | TACR1 | |
| Lanepitant SCHEMBL121512 | 0.99 | TACR1 (1.00) | TACR1 | |
| Lanepitant SCHEMBL8748971 | 0.97 | TACR1 (0.96) | TACR1 | |
| SCHEMBL29407152 | 0.93 | TACR1 (1.00) | TACR1 | |
| SCHEMBL6760488 | 0.93 | TACR1 (1.00) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0693489-B1 | Heterocyclic tachykinin receptor antagonist | LILLY CO ELI (US) | 2001-09-12 | — | — | EP | claimed |
| US-6239144-B1 | ADMINISTERING A TACHYKININ RECEPTOR ANTAGONIST, 2-(N-(2-((4-CYCDOHEXYL)PIPERAZIN-1-YL)ACETYL)AMINO)-3-(1H-INDO L-3-YL)-1-(N-(2-METHOXYBENZYL)ACETYLAMINO)PROPANE, | ELI LILLY AND COMPANY | 2001-05-29 | — | — | US | claimed |
| JP-2000511193-A | — | — | 2000-08-29 | — | — | JP | claimed |
| EP-0912178-A4 | METHODS OF TREATING HYPERTENSION | LILLY CO ELI (US) | 2000-08-16 | — | — | EP | claimed |
| EP-0932406-A4 | METHODS OF TREATING OR PREVENTING INTERSTITIAL CYSTITIS | LILLY CO ELI (US) | 2000-07-05 | — | — | EP | claimed |
| US-6017930-A | Methods of treating or preventing interstitial cystitis | ELI LILLY AND COMPANY (US) | 2000-01-25 | — | — | US | claimed |
| EP-0932406-A1 | METHODS OF TREATING OR PREVENTING INTERSTITIAL CYSTITIS | ELI LILLY AND COMPANY (US) | 1999-08-04 | — | — | EP | claimed |
| EP-0912178-A1 | METHODS OF TREATING HYPERTENSION | ELI LILLY AND COMPANY (US) | 1999-05-06 | — | — | EP | claimed |
| WO-1998043639-A1 | METHODS OF TREATING BONE LOSS | ELI LILLY AND COMPANY (US) | 1998-10-08 | — | — | WO | claimed |
| WO-1997044035-A1 | METHODS OF TREATING HYPERTENSION | ELI LILLY AND COMPANY (US) | 1997-11-27 | — | — | WO | claimed |
| WO-1997033583-A1 | METHODS OF TREATING OR PREVENTING INTERSTITIAL CYSTITIS | ELI LILLY AND COMPANY (US) | 1997-09-18 | — | — | WO | claimed |
| WO-1997031633-A1 | METHODS OF TREATING OR PREVENTING SLEEP APNEA | ELI LILLY AND COMPANY (US) | 1997-09-04 | — | — | WO | claimed |
| EP-0761219-A1 | 2-Acylaminopropanamines as growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 1997-03-12 | — | — | EP | claimed |
| EP-0747055-A2 | Use of tachykinin receptors antagonists for the treatment of cold and allergic rhinitis | ELI LILLY AND COMPANY (US) | 1996-12-11 | — | — | EP | claimed |
| US-5530009-A | TREATING ASTHMA | ELI LILLY AND COMPANY (US) | 1996-06-25 | — | — | US | claimed |
| WO-1996001819-A1 | HETEROCYCLIC TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-01-25 | — | — | WO | claimed |
| EP-0693489-A1 | Heterocyclic tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-01-24 | — | — | EP | claimed |
| EP-0693489-B1 | Heterocyclic tachykinin receptor antagonist | LILLY CO ELI (US) | 2001-09-12 | — | — | EP | disclosed |
| EP-0693489-A1 | Heterocyclic tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0693489-A1 | Heterocyclic tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-01-24 | — | — | EP | disclosed |